| Document |
Document Title |
|
WO/2016/022956A1 |
The invention provides novel asymmetric and symmetric bisaminoquinolmes and related compounds, methods of treatment and syntheses. The novel compounds exhibit effective anticancer activity and are useful in the treatment of a variety of ...
|
|
WO/2016/017467A1 |
This noxious arthropod control agent, which contains an amide compound represented by formula (I) [In the formula, R1 represents a C1-C8 chain hydrocarbon group that may have one or more groups selected from group A, R2 represents a hydr...
|
|
WO/2016/017466A1 |
Provided is a noxious arthropod control agent containing an amide compound represented by formula (I) [In the formula, X represents a nitrogen atom or CH group, p represents 0 or 1, A represents a tetrahydrofuranyl group or the like, R1,...
|
|
WO/2016/012485A1 |
Disclosed are compounds of formula (I) which possess anthelminthic properties wherein the structural elements have the meaning as indicated in the description. Further disclosed are such compounds for the control, treatment and/or preven...
|
|
WO/2016/012560A1 |
The present invention relates to volatile anesthetic halogen compounds for use in preventive and curative treatment of cerebral malaria symptoms.
|
|
WO/2016/008977A1 |
The present invention relates to a Perhexiline compound of formula (I): or a pharmaceutically acceptable salt thereof, for use in the treatment of a pathology caused by trematodes.
|
|
WO/2016/008830A1 |
The invention relates to new aryl-triazolyl pyridines of general formula (I) as pest control agents. The invention also relates to methods for producing the compounds of formula (I). The compounds according to the invention are suitable ...
|
|
WO/2016/009119A1 |
The invention relates to the association of ivermectin and at least one antibiotic compound selected from doxycycline, rifampicin, azithromycin and erythromycin compounds for a therapeutic application requiring a therapeutic treatment ag...
|
|
WO/2016/011019A1 |
The present invention provides small-molecule inhibitors of BMP signaling and compositions and methods for inhibiting BMP signaling. These compounds and compositions may be used to modulate cell growth, differentiation, proliferation, an...
|
|
WO/2016/005577A1 |
This invention is directed to compounds and salts that are generally useful as agents to treat an infection with Dirofilaria immitis. This invention also is directed to treatments comprising the administration of the compounds and salts ...
|
|
WO/2016/005576A1 |
This invention is directed to compounds and salts that are generally useful as agents to treat an infection with Dirofilaria immitis. This invention also is directed to treatments comprising the administration of the compounds and salts ...
|
|
WO/2016/001216A1 |
The invention relates to compositions and to the methods of administration thereof. More specifically, it relates to an optimised method for the administration of active agents to non-human mammals by means of topical application of pre-...
|
|
WO/2016/000827A1 |
The present invention provides compounds of Formula (i). Furthermore, pharmaceutical compositions are provided comprising at least one compound of Formula (i), for the treatment of parasitic diseases including malaria, as well as neurode...
|
|
WO/2015/000431A9 |
Provided are a tizoxanide (TIZ) carbamate compound as represented by formula I, pharmaceutically acceptable salt, hydrate or solvate thereof, and pharmaceutical use of the compound.
|
|
WO/2015/199065A1 |
The present invention provides: a compound represented by formula (I) (in the formula, R1, R2, R3, and R4 each independently indicate a hydrogen atom, C1-6 alkyl group, or the like. R1 and R2 may come together to form a 5- to 6-membered ...
|
|
WO/2015/198247A1 |
The present disclosure relates to methods of preventing or treating parasite infection in a plurality of fish in need thereof, comprising administering to the fish an effective amount of a medicated fish feed. The medicated fish feed com...
|
|
WO/2015/193218A1 |
The invention relates inter alia to halogen-substituted compounds of the compounds of general formulas (I), in which the groups A1-A4, T, W, Q, R1, and Z1-Z3 have the meanings stated in the description. The invention further relates to m...
|
|
WO/2015/193216A1 |
The invention relates to novel pyrazolyl-triazolyl-pyridines of general formula (I), in which the radicals A1-A4, W, Q, R1, R5 and Z1-Z3 have the meaning cited in the description. The invention also relates to methods for producing the c...
|
|
WO/2015/189595A1 |
The invention provides compounds of the formula: wherein L1 and L2 are independently selected from O and S; R1 is C3-C6straight or branched alkyl, C3-C7cycloalkyl, C5-C7cycloalkenyl, adamantly, phenyl or saturated heterocyclyl, any of wh...
|
|
WO/2015/185779A1 |
The invention relates to the use of a corn plant enriched in anti-oxidants or a derivative of same, to produce a medication, nutritional composition or nutraceutical for the prevention or treatment of coccidiosis, pododermatitis or ulcer...
|
|
WO/2015/182754A1 |
[Problem] To provide: a control method for Dermanyssus gallinae, said method comprising inducing an immune reaction against D. gallinae in livestock; a vaccine antigen usable therefor; and a vaccine against D. gallinae. [Solution] A meth...
|
|
WO/2015/179414A1 |
The present invention relates to novel anthelmintic compounds of formula (I) below: [Formula should be inserted here] wherein Y and Z are independently a bicyclic carbocyclic or a bicyclic heterocyclic group, or one of Y or Z is a bicycl...
|
|
WO/2015/179840A1 |
Disclosed herein are embodiments of a combination and/or composition for administration to animals. In some embodiments, the combination and/or composition can be administered to treat and/or prevent a disease in animals. In some embodim...
|
|
WO/2015/178940A1 |
The invention pertains to ligands that bind to CD81 and that inhibit or block Plasmodium attachment to CD81, compositions and methods for preventing, inhibiting or treating infection by Plasmodium and ligands that target a Plasmodium bin...
|
|
WO/2015/172196A1 |
Novel heterocyclic compounds are provided which display useful efficacy in the treatment of diseases caused by trypanosomatids. Particularly, the compounds of the invention are useful in the treatment of HAT and/or Chagas disease and/or ...
|
|
WO/2015/165660A1 |
The present invention relates to triaminopyrimidines and to pharmaceutically acceptable salts thereof, to their use in the treatment and or prevention of malaria caused by plasmodium species, and to their methods of preparation.
|
|
WO/2015/163280A1 |
A parasite control agent or parasiticide that has an exceptional effect for controlling or exterminating parasites, especially endoparasites, and that can be safely used contains as an active ingredient at least one selected from compoun...
|
|
WO/2015/164573A1 |
Provided are novel compounds, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are inhibitors of CD73 and are useful in the treatment of cancer.
|
|
WO/2015/164480A1 |
The present invention relates to substituted pyrrolopyridinones and substituted pyrazolopyridinones which are inhibitors of BET proteins such as BRD2, BRD3, BRD4, and BRD-t and are useful in the treatment of diseases such as cancer.
|
|
WO/2015/155293A1 |
The invention relates to Quillaja Saponaria saponins or a composition comprising Quillaja Saponaria saponins for use in the prevention and/or treatment of an ectoparasitic infection or infestation in fish. The present invention also rela...
|
|
WO/2015/157639A1 |
Disclosed are methods of treating individuals with yeast-based immunotherapy who have been preselected as being sensitive to type I interferons, as well as methods for selecting individuals for treatment with yeast-based immunotherapeuti...
|
|
WO/2015/147655A1 |
Described herein are stable veterinary formulations and methods of treatment and use, comprising at least one macrocyclic lactone and levamisole as active anthelmintic agents, optionally also with at least one benzimidazole class anthelm...
|
|
WO/2015/143536A1 |
This disclosure describes compounds that affect the olfactory responses of the honey bee mite (Varroa destructor) and methods of use thereof. The compounds do not kill Varroa destructor, and are therefore unlikely to generate Varroa dest...
|
|
WO/2015/146581A1 |
[Problem] To provide a method for economically and simply enhancing the epidemic prevention ability of fish. [Solution] An epidemic prevention method for fish, said method comprising feeding the fish with a feed, which contains protein-r...
|
|
WO/2015/147313A1 |
A tetrazolinone compound shown by formula (1) (in the formula, X represents CR6 or a nitrogen atom; R1, R2, R3, R4, and R6 each independently represent a halogen atom, C1-C4 alkyl group optionally having one or more halogen atoms, or the...
|
|
WO/2015/147335A1 |
The present invention relates to a cerebral malaria marker and techniques for the application thereof. A marker for identifying cerebral malaria, said marker being based on the state of olfactory bulb or comprising a factor in the CCL21-...
|
|
WO/2015/147314A1 |
In the present invention, a harmful organism control agent containing an aromatic compound represented by formula (1) [in the formula, R1 represents a halogen atom or the like; R3 represents a hydrogen atom or the like; R7 represents a C...
|
|
WO/2015/147336A1 |
In the present invention. a harmful organism control agent containing an aromatic compound represented by formula (1) [in the formula, R1 represents a C1-C4 alkyl group or the like; R3 represents a hydrogen atom or the like; R7 represent...
|
|
WO/2015/147022A1 |
An isoxazolin-5-carboxamide compound represented by formula (I) or a salt thereof, and a pesticide, miticide, or insecticide containing at least one selected from these compounds. In formula (I), Cy indicates a pyridyl group or the like ...
|
|
WO/2015/146849A1 |
[Problem] To provide a malaria transmission prevention agent or a malarial parasite growth regulating agent, as a result of finding a drug that inhibits the growth of the malarial parasite inside the body of a vector mosquito. [Solution]...
|
|
WO/2015/144813A1 |
The present invention relates to N-acylimino compound of formula (I). The invention also relates to the use of the N-acylimino heterocyclic compounds of formula (I), their stereoisomers, their tautomers and their salts, for combating inv...
|
|
WO/2015/138496A1 |
Tricyclic chemical modulators of protein phosphatase 2A are disclosed. The compounds are useful to treat cancer, age-onset proteotoxicity, stress-induced depression, inflammation, and acne. The compounds are of the following phenothiazin...
|
|
WO/2015/135926A1 |
The present invention relates to a pharmaceutically acceptable dichloroacetate compound selected from a salt of dichloroacetic acid, an ester of dichloroacetic acid with a C1-C6 alkanol, C1-C6 acyloxy-methanol or C1-C6 alkoxycarbonyloxy-...
|
|
WO/2015/133603A1 |
Provided are: a fused heterocyclic compound represented by formula (1) or an N-oxide thereof, having excellent control effects against pests; a pest control composition containing the abovementioned compound and an inert carrier; and a p...
|
|
WO/2015/133280A1 |
The present invention addresses the problem of providing a novel compound effective against malaria, and an application for the same. Provided is an asymmetrical compound group synthesized on the basis of a molecular design aimed at inte...
|
|
WO/2015/133511A1 |
Provided is an endoparasite control agent that includes, as an active ingredient, a carboxamide derivative represented by general formula (I) or salts thereof in order to provide a novel endoparasite control agent such as an insecticide ...
|
|
WO/2015/133512A1 |
Provided is an endoparasite control agent that includes, as an active ingredient, a heterocyclic carboxamide derivative represented by general formula (I) or salts thereof in order to provide a novel endoparasite control agent such as an...
|
|
WO/2015/131231A1 |
A method for preventing, treating and/or reversing a disease, condition or state in a subject in need thereof by administering to the subject an effective amount of the (-)-perhexiline or a pharmaceutically acceptable salt, prodrug or de...
|
|
WO/2015/127537A1 |
The present document describes a powder composition comprising a functionalized starch having a single helix V-structure and having a degree of substitution of at least 0.25, and a bioactive agent, forming an inclusion complex with said ...
|
|
WO/2015/127548A1 |
The invention encompasses the novel class of compounds represented by the Formula (I) below, which are inhibitors of the TC-PTP enzyme. The invention also encompasses pharmaceutical compositions which include the compounds shown above an...
|
